Company intelligence / Profile preview
Nyrada Inc
Sydney, NSW, Australianyrada.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
In February 2024, NYR-BI03 showed 42% rescue of brain tissue in stroke models. In October 2024, NYR-BI03 demonstrated 86% cardioprotective effect following myocardial ischemic-reperfusion injury. In April 2025, NYR-BI03 showed statistically significant neuroprotective effect in traumatic brain injury models (p = 0.043; ANOVA).[5]
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Walter Reed Army Institute of ResearchUNSW Sydney[5]
Beyond the preview
Go deeper on Nyrada Inc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nyrada Inc.